1. Scrip
  2. >>Business
  3. >>Deals

FTC Is Taking A Tougher Stance On Pharma; A Deputy Director Explains Why

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Deputy director of the Bureau of Competition Rahul Rao discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.

• Source: Shutterstock

Federal Trade Commission Deputy director of the Bureau of Competition Rahul Rao said the regulatory group’s tougher stance on pharmaceutical deals stems from a general view that market incentives in the sector had grown misaligned with competitive practices.

Key Takeaways

  • FTC deputy director of the Bureau of Competition Rahul Rao discussed some of the agency’s recent actions on pharma deals.

“There wasn’t a seismic event that happened,” he said. “What we are seeing is greater consolidation. We’re seeing the effects...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.